论文部分内容阅读
目的检测ＥＲ、ＥＧＦＲ、ｐ５３蛋白过度表达与乳腺癌患者预后的关系，探讨其作为预后指标的可行性。方法共１２０例原发乳腺癌细针穿刺涂片标本，采用免疫细胞化学方法。结果（１）ＥＲ在腋淋巴结无转移和临床分期低的病例中表达率高。（２）ＥＧＦＲ在腋淋巴结有转移、临床分期高、ＥＲ阴性的病例中表达率高，与腋淋巴结转移、临床分期呈正相关（Ｐ＜０．０５），与ＥＲ呈负相关（Ｐ＜０．０５）。（３）ｐ５３与腋淋巴结转移、临床分期、ＥＧＦＲ呈正相关（Ｐ＜０．０５），与ＥＲ呈负相关（Ｐ＜０．０５）。结论乳腺癌患者ＥＲ过度表达者预后好，ＥＧＦＲ、ｐ５３过度表达者预后不良，它们可以作为判断乳腺癌患者预后的有效指标，将其应用于临床，辅助判断病人预后，可能具有重要意义
Objective To investigate the relationship between the overexpression of ER, EGFR and p53 protein and prognosis of breast cancer patients, and to explore its feasibility as a prognostic indicator. Methods A total of 120 cases of primary fine-needle aspiration needle smears of breast cancer were obtained by immunocytochemistry. Results (1) ER was highly expressed in cases with no metastatic axillary lymph nodes and low clinical stage. (2) The expression rate of EGFR was high in axillary lymph node metastasis, high clinical stage, and ER negative cases. It was positively correlated with axillary lymph node metastasis and clinical stage (P<0.05) and negatively correlated with ER (P<0. 05). (3) p53 was positively correlated with axillary lymph node metastasis, clinical stage, EGFR (P<0.05), and negatively correlated with ER (P<0.05). Conclusions The prognosis of breast cancer patients with overexpression of ER is good, and the prognosis of patients with overexpression of EGFR and p53 is a poor prognosis. They can be used as an effective index to judge the prognosis of breast cancer patients. It can be used clinically to help determine the prognosis of patients and may be of great significance.